Table 2 Clinical Trial Design Data
Study type | ||
Interventional | 117 | 97% |
Expanded Access | 4 | 3% |
Trial phase | ||
NR | 43 | 36% |
Early Phase 1 | 6 | 5% |
Phase 1 | 15 | 12% |
Phase 1/Phase 2 | 13 | 11% |
Phase 2 | 29 | 24% |
Phase 2/Phase 3 | 7 | 6% |
Phase 3 | 7 | 6% |
Phase 4 | 1 | 1% |
Allocation | ||
NR | 113 | 93% |
Non-Randomized | 18 | 15% |
Randomized | 6 | 5% |
Interventional model | ||
Single Group Assignment | 102 | 84% |
Parallel Assignment | 14 | 12% |
NR | 20 | 17% |
Crossover assignment | 1 | 1% |
Masking (Blinding) | ||
Open Label | 96 | 79% |
NR | 21 | 17% |
Masked (Blinded) | 4 | 3% |
Number of arms | ||
1 | 96 | 79% |
2 | 11 | 9% |
3 | 7 | 6% |
NR | 7 | 6% |
Number of reported primary outcomes | ||
NR | 4 | |
1 | 88 | |
2 | 11 | |
3 | 10 | |
≥ 4 | 8 | |
Number of reported secondary outcomes | ||
NR | 44 | |
1 | 32 | |
2 | 13 | |
3 | 6 | |
≥ 4 | 26 | |